Lanean...

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with liraglutide and semaglutide, 2 glucagon-like peptide-1 receptor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Circ Res
Egile nagusia: Scheen, André J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5959222/
https://ncbi.nlm.nih.gov/pubmed/29748368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.117.311588
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!